Shares of Sarepta Therapeutics SRPT rose nearly 14% on Tuesday after announcing that it has entered into an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals ARWR.

Gil Blum, an analyst from Needham, reiterated the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The associated price target was ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.C2GW7kSb.js ...

Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterated a Buy ...

Shares of Sarepta Therapeutics (SRPT) have gained 0.2% over the past four weeks to close the last trading session at $130.50, but there could still be a solid upside left in the stock if short-term ...

H.C. Wainwright has recently initiated Sarepta Therapeutics Inc (SRPT) stock to Sell rating, as announced on November 25, 2024, according to Finviz. Earlier, on November 7, 2024, Cantor Fitzgerald had ...

Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based ...

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Arrowhead Pharmaceuticals (ARWR) has secured a new partnership with Sarepta Therapeutics (SRPT). Under the terms of the deal, ...

Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...